Occurrences of opportunistic infections in chronic myelogenous leukemia patients treated with imatinib mesylate

Leukemia Research

Volumn 34, Issue 9, 2010, Pages 1250-1251

  Anthony, Navin ^a   Shanks, James ^a   Terebelo, Howard ^a  

^a PROVIDENCE HOSPITAL   (United States)

Author keywords

Chronic myelogenous leukemia; Imatinib; Immunomodulatory; Opportunistic infection; Tyrosine kinase inhibitor

Indexed keywords

AMPHOTERICIN B; BUSULFAN; DASATINIB; FLUCYTOSINE; HYDROXYUREA; IMATINIB;

ADULT; ARTICLE; AXILLARY LYMPH NODE; CASE REPORT; CEREBROSPINAL FLUID EXAMINATION; CHRONIC MYELOID LEUKEMIA; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN HERPESVIRUS 8; KAPOSI SARCOMA; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MALE; OPPORTUNISTIC INFECTION; PANCYTOPENIA; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PULMONARY CRYPTOCOCCOSIS; SPLENOMEGALY;

EID: 77955267032     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.05.019     Document Type: Article

References (10)

1. Schade A.E., Schieven G.L., Townsend R., et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008, 111:1366-1377.
2. Dietz A.B., Souan L., Knutson G.J., et al. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004, 104:1094-1099.
3. Seggewiss R., Lore K., Greiner E., et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005, 105:2473-2479.
4. Sinai P., Berg R.E., Haynie J.M., et al. Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo. J Immunol 2007, 178:2028-2037.
5. Imatinib Mesylate [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2008.
6. Mattiuzzi G.N., Cortes J.E., Talpaz M., et al. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res 2003, 9:976-980.
7. Ikeda K., Shiga Y., Takahashi A., et al. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma 2006, 47:155-157.
8. Bekkenk M.W., Vermeer M.H., Meijer C.J., et al. EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate. Blood 2003, 102:4243.
9. Cwynarski K., Laylor R., Macchiarulo E., et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004, 18:1332-1339.
10. Appel S., Boehmler A.M., Grunebach F., et al. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 2004, 103:538-544.